SDC1 and acute myeloid leukemia: In contrast to our results, Larsen et al. found that syndecan-1 was not predictive of the outcome in AML patients, but it has more clinical significance because a high expression of serum syndecan-1 is associated with bleeding, thrombocytopenia, leukocytosis, and endothelial cell damage [17].